Dennis Arsenault couldn’t believe what he was seeing. When his company, OrganiGram Inc., made its debut on the TSX Venture Exchange this summer, the shares suddenly shot up.

Such a high valuation didn’t make sense – not even to Mr. Arsenault, and he was the company’s chief executive officer.

Just a few weeks earlier, OrganiGram, an upstart producer of medical marijuana based in Moncton had been valued privately at just over $40-million. But on the open market, speculators feverishly drove up the total value of shares to nearly $120-million in late August.

It wasn’t that Mr. Arsenault didn’t believe in the future of his business. OrganiGram is one of only 15 companies to land a highly coveted federal licence in Canada’s new medical marijuana sector, touted as a potential multibillion-dollar industry in the years to come.

But the company hadn’t made a dime yet. OrganiGram was probably a year away from pulling in meaningful revenue – and it was already worth nine digits in the stock market.

“I was just shaking my head,” Mr. Arsenault said of that first week of trading.

What happened was exuberant, if irrational, and OrganiGram wasn’t the only company feeling the surge.

Read the rest of the article here.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

4Front Ventures Corp. (FFNTF) Announces Participation at Canaccord Genuity Virtual Cannabis Conference

4Front Ventures Announces Participation at Canaccord Genuity Virtual Cannabis Conference 4Front Ventures…

Maryland Pro-Cannabis Lawmaker States that he Should have Disclosed Business Ties

The state legislature that supported the legalization of medical cannabis in Maryland…